Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
Top Cited Papers
- 7 November 2004
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 10 (12), 1344-1351
- https://doi.org/10.1038/nm1135
Abstract
We identify berberine (BBR), a compound isolated from a Chinese herb, as a new cholesterol-lowering drug. Oral administration of BBR in 32 hypercholesterolemic patients for 3 months reduced serum cholesterol by 29%, triglycerides by 35% and LDL-cholesterol by 25%. Treatment of hyperlipidemic hamsters with BBR reduced serum cholesterol by 40% and LDL-cholesterol by 42%, with a 3.5-fold increase in hepatic LDLR mRNA and a 2.6-fold increase in hepatic LDLR protein. Using human hepatoma cells, we show that BBR upregulates LDLR expression independent of sterol regulatory element binding proteins, but dependent on ERK activation. BBR elevates LDLR expression through a post-transcriptional mechanism that stabilizes the mRNA. Using a heterologous system with luciferase as a reporter, we further identify the 5′ proximal section of the LDLR mRNA 3′ untranslated region responsible for the regulatory effect of BBR. These findings show BBR as a new hypolipidemic drug with a mechanism of action different from that of statin drugs.Keywords
This publication has 35 references indexed in Scilit:
- Effect of YM‐53601, a novel squalene synthase inhibitor, on the clearance rate of plasma LDL and VLDL in hamstersBritish Journal of Pharmacology, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Doubling Expression of the Low Density Lipoprotein Receptor by Truncation of the 3′-Untranslated Region Sequence Ameliorates Type III Hyperlipoproteinemia in Mice Expressing the Human ApoE2 IsoformPublished by Elsevier BV ,2001
- Identification of a Novel Sterol-independent Regulatory Element in the Human Low Density Lipoprotein Receptor PromoterPublished by Elsevier BV ,2000
- ONCOSTATIN M-SPECIFIC RECEPTOR EXPRESSION AND FUNCTION IN REGULATING CELL PROLIFERATION OF NORMAL AND MALIGNANT MAMMARY EPITHELIAL CELLSCytokine, 1998
- Dietary fatty acids regulate hepatic low density lipoprotein (LDL) transport by altering LDL receptor protein and mRNA levels.JCI Insight, 1993
- Regulation of the mevalonate pathwayNature, 1990
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- The human LDL receptor: A cysteine-rich protein with multiple Alu sequences in its mRNACell, 1984